Clinical trials: Bullous Pemphigoid
Bullous Pemphigoid
Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid
Clinical observation frequently shows a paradoxical effect of topical corticosteroids in charge of a sudden melting of edema in the first days of treatment, which could be due to mobilization of extracellular.
- Trial name
- RECOPB (NCT02360202)
- Testing
- Impedance analysis, Clobetasol Propionate cream treatment
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Rouen
Bullous Pemphigoid
Efficacy and Safety of add-on Dapsone Versus add-on Methotrexate in Patients With Bullous Pemphigoid
Bullous pemphigoid (BP) is an autoimmune subepidermal blistering disorder most commonly affecting the older population between 60-80 years old.
- Trial name
- NCT05984381
- Testing
- Prednisolone, Dapsone, Methotrexate
- Where
- India
- Volunteers
- 62 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Alkaline Chemical Burn Of Cornea And Conjunctival Sac, Acid Chemical Burn Of Cornea And Conjunctival Sac
The Improvement of Limbal Epithelial Culture Technique by Using Collagenase to Isolate Limbal Stem Cells
Using collagenase to isolate limbal stem cells and improve the technique of ex vivo expansion of limbal stem cells for the treatment of patients suffering from unilateral limbal stem cell insufficiency based on the concept of…
- Conditions
- Alkaline Chemical Burn Of Cornea And Conjunctival Sac, Acid Chemical Burn Of Cornea And Conjunctival Sac, Benign Mucous Membrane Pemphigoid With Ocular Involvement
- Trial name
- NCT02202642
- Testing
- collagenase
- Where
- Taiwan
- Volunteers
- 10 people
- Sponsor
- National Taiwan University Hospital
Bullous Pemphigoid
A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid
ARGX-113-2009 is an operationally seamless 2-part, phase 2/3, prospective, global, multicenter, randomized, double-blinded, placebo-controlled study to investigate the efficacy, safety, tolerability, immunogenicity…
- Trial name
- BALLAD (NCT05267600)
- Testing
- efgartigimod PH20 SC, Prednisone
- Where
- 129 sites in United States, Australia and 19 more
- Volunteers
- 98 people
- Sponsor
- argenx
Bullous Pemphigoid
Genetic Susceptibility and Influence of the Microbiomae in Bullous Pemphigoid
Autoimmune bullous dermatoses include pemphigus, bullous pemphigoid, pemphigoid gestationis, linear IgA dermatosis, mucous membrane pemphigoid, lichen planus pemphigoid, anti-p200 pemphigoid, epidermolysis bullosa acquisita and…
- Trial name
- MICROPB (NCT02874079)
- Testing
- Blood sample and cotton skin swabs
- Where
- France
- Volunteers
- 100 people
- Sponsor
- CHU de Reims
Bullous Pemphigoid
Compassionate Use of Dupilumab for Adult Patients With Bullous Pemphigoid
The objective of the program is to provide patients with Bullous Pemphigoid (BP), that participated in the R668-BP-1902 (NCT04206553) phase 2/3 study, dupilumab treatment and evaluate the long-term safety of dupilumab.
- Trial name
- NCT05906706
- Testing
- dupilumab
- Sponsor
- Regeneron Pharmaceuticals
Bullous Pemphigoid (BP)
rVA576 in Adult Mild to Moderate Bullous Pemphigoid Subjects
Bullous pemphigoid (BP) is the most common of the autoimmune blistering skin diseases in Western Europe. [Joly 2012]The study will recruit the new onset or relapsing mild to moderate BP patients.
- Trial name
- NCT04035733
- Testing
- rVA576
- Where
- 2 sites in Germany, Netherlands
- Volunteers
- 9 people
- Sponsor
- AKARI Therapeutics
Pemphigoid, Bullous, Adrenal Insufficiency
Screening for Adrenal Insufficiency During Dermocorticoid Reduction in Bullous Pemphigoid (BP)
The braking of the corticotropic axis is well established during the induction phase of superpotent topical corticosteroid therapy (clobetasol propionate) in bullous pemphigoid (BP).
- Trial name
- PB-DEPIST (NCT06148090)
- Testing
- clobetasol decreasing measurement
- Where
- 5 sites in France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Bordeaux
Pemphigoid, Bullous
Anti-IL-5 Therapy in Bullous Pemphigoid (BP)
Randomized, placebo-controlled, double-blind study evaluating the effect of anti-IL-5-therapy in patients with bullous pemphigoid.
- Trial name
- NCT01705795
- Testing
- Mepolizumab (a-IL-5 antibody)
- Where
- Switzerland
- Volunteers
- 32 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Bullous Pemphigoid
Validation of a Simplified Severity Score (Investigator Global Assessment: IGA) in Bullous Pemphigoid
The aim of the study is to validate a global and simple score : IGA (Investigator Global Assessment) score for the evaluation of the extent and severity of the disease in patients with bullous pemphigoid
- Trial name
- IGA score (NCT05366127)
- Testing
- IGA score, BULLOUS PEMPHIGOID DISEASE AREA INDEX (BPDAI)
- Where
- 11 sites in France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Rouen
Glaucoma, Blindness, Acquired
Implantable Intraocular Pressure Sensor for Glaucoma Monitoring in Patients With Boston Keratoprosthesis Type 1
The purpose of this study is to evaluate the safety and performance of the EYEMATE system in patients undergoing concomitant implantation of a BKPro type 1 and an EYEMATE sensor over the 24 months period beginning at implantation.
- Conditions
- Glaucoma, Blindness, Acquired, Keratitis, Herpetic, Ocular Cicatricial Pemphigoid
- Trial name
- BKPro (NCT03421548)
- Testing
- EyeMate
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Bullous Pemphigoid
Topical Steroids Alone or Associated With Methotrexate in Bullous Pemphigoid
This controlled multi-center randomized clinical trial, with direct individual benefit, will compare efficacy and safety of two strategies in non-localized BP care: a combined regimen using initial superpotent topical steroids…
- Trial name
- BP/MTX (NCT02313870)
- Testing
- clobetasol propionate + Methotrexate, clobetasol propionate alone
- Where
- France
- Volunteers
- 322 people
- Sponsor
- University Hospital, Montpellier
Bullous Pemphigoid, Pruritus
Explore the Mechanisms of Pruritus in Bullous Pemphigoid Patients During Remission
The following is the investigators hypothesis regarding the pruritus of BP patients during remission. Anti-BP 180 IgE binds to dermal mast cells, inducing their activation and secretion of mediators after being cross-linked by…
- Trial name
- NCT01265082
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- National Taiwan University Hospital
Bullous Pemphigoid
Efficiency and Tolerance of Rituximab (mabthéra) in Bullous Pemphigoid
The aim of the study is to assess that it will be possible to control with a single cycle of rituximab patient with bullous pemphigoid.
- Trial name
- Rituximab2 (NCT00525616)
- Testing
- Mabthera
- Where
- France
- Volunteers
- 18 people
- Sponsor
- University Hospital, Rouen
Bullous Pemphigoid
A Proof-of-Concept Study of Topical AC-203 in Patients With Bullous Pemphigoid
Bullous pemphigoid (BP) is a chronic, inflammatory, subepidermal, autoimmune blistering disease which mainly develops in the elderly, with onset usually in the late 70s and a substantial increase in incidence in people older than…
- Trial name
- NCT03286582
- Testing
- AC-203 1% Topical Ointment, Clobetasol 0.05% Topical Ointment
- Where
- Taiwan
- Volunteers
- 10 people
- Sponsor
- TWi Biotechnology, Inc.
Pemphigoid, Bullous
A Study to Assess the Therapeutic Effect and Safety of Adjunctive AKST4290 in Subjects With Bullous Pemphigoid
This study will evaluate the therapeutic effect and safety of adjunctive AKST4290 in subjects with bullous pemphigoid (BP).
- Trial name
- NCT04499235
- Testing
- Mometasone furoate, AKST4290
- Where
- 8 sites in Germany
- Volunteers
- 6 people
- Sponsor
- Alkahest, Inc.
Bullous Pemphigoid
Phase III Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids
Patients diagnosed with bullous pemphigoid were confirmed based on the investigators national diagnostic criteria. Patients who meet all inclusion criteria and do not conflict with the exclusion criteria will receive NPB-01…
- Trial name
- NCT01408550
- Testing
- NPB-01
- Where
- Japan
- Volunteers
- 56 people
- Sponsor
- Nihon Pharmaceutical Co., Ltd
Bullous Pemphigoid
Pilot Efficacy and Safety Study of Oral DF2156A in Patients With Active Bullous Pemphigoid
The objective of this clinical trial was to evaluate whether DF2156A has a potential in improving the clinical outcome in patients with active blistering bullous pemphigoid (BP) to warrant its further development.
- Trial name
- NCT01571895
- Testing
- DF2156A
- Where
- 4 sites in Germany, Italy
- Volunteers
- 4 people
- Sponsor
- Dompé Farmaceutici S.p.A
Bullous Pemphigoid, Immunotherapy
Bullous Pemphigoid Induced by antiPD-1/PDL-1 Therapy
Immune checkpoint inhibitors (monoclonal antibodies targeting cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD- L1)) have revolutionized the treatment…
- Conditions
- Bullous Pemphigoid, Immunotherapy, Programmed Cell Death Ligand 1
- Trial name
- NCT04641884
- Testing
- Not concerned
- Where
- France
- Volunteers
- 85 people
- Sponsor
- Nantes University Hospital
Bullous Pemphigoid
Retrospective Study of the Effects of Sub-pathologic Phenotypes of BP on Clinical Management and Prognosis
Bullous pemphigoid (BP) is a chronic autoimmune subepidermal blistering disease primarily affecting the elderly with a significant risk of mortality and morbidity.
- Trial name
- BP (NCT06213909)
- Testing
- This is a retrospective analysis of health data from inpatient record, no intervention was designed
- Where
- China
- Volunteers
- 318 people
- Sponsor
- Xijing Hospital